Ambarish Pandey1, Wally Omar1, Colby Ayers1,2, Michael LaMonte3, Liviu Klein4, Norrina B Allen5, Lewis H Kuller6, Philip Greenland5, Charles B Eaton7, John S Gottdiener8, Donald M Lloyd-Jones5, Jarett D Berry9,2. 1. Division of Cardiology (A.P., W.O., C.A., J.D.B.). 2. Department of Clinical Sciences (C.A., J.D.B.). 3. University of Texas Southwestern Medical Center, Dallas. Department of Epidemiology and Environmental Health, School of Public Health and Health Professions, University of Buffalo, NY (M.L.). 4. Division of Cardiology, University of California San Francisco (L.K.). 5. Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL (N.B.A., P.G., D.M.L.-J.). 6. Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, PA (L.H.K.). 7. Department of Epidemiology, School of Public Health and Department of Family Medicine, Alpert Medical School, Brown University, Providence, RI (C.B.E.). 8. Division of Cardiology, Department of Internal Medicine, University of Maryland School of Medicine, Baltimore (J.S.G.). 9. Division of Cardiology (A.P., W.O., C.A., J.D.B.) jarett.berry@utsouthwestern.edu.
Abstract
BACKGROUND: Lifetime risk of heart failure has been estimated to range from 20% to 46% in diverse sex and race groups. However, lifetime risk estimates for the 2 HF phenotypes, HF with preserved ejection fraction (HFpEF) and HF with reduced ejection fraction (HFrEF), are not known. METHODS: Participant-level data from 2 large prospective cohort studies, the CHS (Cardiovascular Health Study) and MESA (Multiethnic Study of Atherosclerosis), were pooled, excluding individuals with prevalent HF at baseline. Remaining lifetime risk estimates for HFpEF (EF ≥45%) and HFrEF (EF <45%) were determined at different index ages with the use of a modified Kaplan-Meier method with mortality and the other HF subtype as competing risks. RESULTS: We included 12 417 participants >45 years of age (22.2% blacks, 44.8% men) who were followed up for median duration of 11.6 years with 2178 overall incident HF events with 561 HFrEF events and 726 HFpEF events. At the index age of 45 years, the lifetime risk for any HF through 90 years of age was higher in men than women (27.4% versus 23.8%). Among HF subtypes, the lifetime risk for HFrEF was higher in men than women (10.6% versus 5.8%). In contrast, the lifetime risk for HFpEF was similar in men and women. In race-stratified analyses, lifetime risk for overall HF was higher in nonblacks than blacks (25.9% versus 22.4%). Among HF subtypes, the lifetime risk for HFpEF was higher in nonblacks than blacks (11.2% versus 7.7%), whereas that for HFrEF was similar across the 2 groups. Among participants with antecedent myocardial infarction before HF diagnosis, the remaining lifetime risks for HFpEF and HFrEF were up to 2.5-fold and 4-fold higher, respectively, compared with those without antecedent myocardial infarction. CONCLUSIONS: Lifetime risks for HFpEF and HFrEF vary by sex, race, and history of antecedent myocardial infarction. These insights into the distribution of HF risk and its subtypes could inform the development of targeted strategies to improve population-level HF prevention and control.
BACKGROUND: Lifetime risk of heart failure has been estimated to range from 20% to 46% in diverse sex and race groups. However, lifetime risk estimates for the 2 HF phenotypes, HF with preserved ejection fraction (HFpEF) and HF with reduced ejection fraction (HFrEF), are not known. METHODS:Participant-level data from 2 large prospective cohort studies, the CHS (Cardiovascular Health Study) and MESA (Multiethnic Study of Atherosclerosis), were pooled, excluding individuals with prevalent HF at baseline. Remaining lifetime risk estimates for HFpEF (EF ≥45%) and HFrEF (EF <45%) were determined at different index ages with the use of a modified Kaplan-Meier method with mortality and the other HF subtype as competing risks. RESULTS: We included 12 417 participants >45 years of age (22.2% blacks, 44.8% men) who were followed up for median duration of 11.6 years with 2178 overall incident HF events with 561 HFrEF events and 726 HFpEF events. At the index age of 45 years, the lifetime risk for any HF through 90 years of age was higher in men than women (27.4% versus 23.8%). Among HF subtypes, the lifetime risk for HFrEF was higher in men than women (10.6% versus 5.8%). In contrast, the lifetime risk for HFpEF was similar in men and women. In race-stratified analyses, lifetime risk for overall HF was higher in nonblacks than blacks (25.9% versus 22.4%). Among HF subtypes, the lifetime risk for HFpEF was higher in nonblacks than blacks (11.2% versus 7.7%), whereas that for HFrEF was similar across the 2 groups. Among participants with antecedent myocardial infarction before HF diagnosis, the remaining lifetime risks for HFpEF and HFrEF were up to 2.5-fold and 4-fold higher, respectively, compared with those without antecedent myocardial infarction. CONCLUSIONS: Lifetime risks for HFpEF and HFrEF vary by sex, race, and history of antecedent myocardial infarction. These insights into the distribution of HF risk and its subtypes could inform the development of targeted strategies to improve population-level HF prevention and control.
Authors: Sanjiv J Shah; Dalane W Kitzman; Barry A Borlaug; Loek van Heerebeek; Michael R Zile; David A Kass; Walter J Paulus Journal: Circulation Date: 2016-07-05 Impact factor: 29.690
Authors: Donald M Lloyd-Jones; Martin G Larson; Eric P Leip; Alexa Beiser; Ralph B D'Agostino; William B Kannel; Joanne M Murabito; Ramachandran S Vasan; Emelia J Benjamin; Daniel Levy Journal: Circulation Date: 2002-12-10 Impact factor: 29.690
Authors: Yariv Gerber; Susan A Weston; Margaret M Redfield; Alanna M Chamberlain; Sheila M Manemann; Ruoxiang Jiang; Jill M Killian; Véronique L Roger Journal: JAMA Intern Med Date: 2015-06 Impact factor: 21.873
Authors: Jennifer E Ho; Asya Lyass; Douglas S Lee; Ramachandran S Vasan; William B Kannel; Martin G Larson; Daniel Levy Journal: Circ Heart Fail Date: 2012-12-27 Impact factor: 8.790
Authors: Gysèle S Bleumink; Anneke M Knetsch; Miriam C J M Sturkenboom; Sabine M J M Straus; Albert Hofman; Jaap W Deckers; Jacqueline C M Witteman; Bruno H Ch Stricker Journal: Eur Heart J Date: 2004-09 Impact factor: 29.983
Authors: Charles B Eaton; Mary Pettinger; Jacques Rossouw; Lisa Warsinger Martin; Randi Foraker; Abdullah Quddus; Simin Liu; Nina S Wampler; Wen-Chih Hank Wu; JoAnn E Manson; Karen Margolis; Karen C Johnson; Matthew Allison; Giselle Corbie-Smith; Wayne Rosamond; Khadijah Breathett; Liviu Klein Journal: Circ Heart Fail Date: 2016-10 Impact factor: 8.790
Authors: Jennifer E Ho; Danielle Enserro; Frank P Brouwers; Jorge R Kizer; Sanjiv J Shah; Bruce M Psaty; Traci M Bartz; Rajalakshmi Santhanakrishnan; Douglas S Lee; Cheeling Chan; Kiang Liu; Michael J Blaha; Hans L Hillege; Pim van der Harst; Wiek H van Gilst; Willem J Kop; Ron T Gansevoort; Ramachandran S Vasan; Julius M Gardin; Daniel Levy; John S Gottdiener; Rudolf A de Boer; Martin G Larson Journal: Circ Heart Fail Date: 2016-06 Impact factor: 8.790
Authors: Lisandro D Colantonio; Christopher M Gamboa; Joshua S Richman; Emily B Levitan; Elsayed Z Soliman; George Howard; Monika M Safford Journal: Circulation Date: 2017-07-11 Impact factor: 29.690
Authors: Nirav Patel; Mary Cushman; Orlando M Gutiérrez; George Howard; Monika M Safford; Paul Muntner; Raegan W Durant; Sumanth D Prabhu; Garima Arora; Emily B Levitan; Pankaj Arora Journal: JCI Insight Date: 2019-06-04
Authors: Alanna M Chamberlain; Cynthia M Boyd; Sheila M Manemann; Shannon M Dunlay; Yariv Gerber; Jill M Killian; Susan A Weston; Véronique L Roger Journal: Am J Med Date: 2019-11-17 Impact factor: 4.965
Authors: Ambarish Pandey; Muthiah Vaduganathan; Sameer Arora; Arman Qamar; Robert J Mentz; Sanjiv J Shah; Patricia P Chang; Stuart D Russell; Wayne D Rosamond; Melissa C Caughey Journal: Circulation Date: 2020-06-03 Impact factor: 29.690
Authors: Philip Brainin; Sofie Reumert Biering-Sørensen; Rasmus Møgelvang; Martina Chantal de Knegt; Flemming Javier Olsen; Søren Galatius; Gunnar Hilmar Gislason; Jan Skov Jensen; Tor Biering-Sørensen Journal: Int J Cardiovasc Imaging Date: 2018-10-19 Impact factor: 2.357
Authors: Magnus T Jensen; Peter Sogaard; Ida Gustafsson; Jan Bech; Thomas F Hansen; Thomas Almdal; Simone Theilade; Tor Biering-Sørensen; Peter G Jørgensen; Søren Galatius; Henrik U Andersen; Peter Rossing Journal: Diabetologia Date: 2019-10-30 Impact factor: 10.122
Authors: Amanda M Perak; Sadiya S Khan; Laura A Colangelo; Samuel S Gidding; Anderson C Armstrong; Cora E Lewis; Jared P Reis; Pamela J Schreiner; Stephen Sidney; Joao A C Lima; Donald M Lloyd-Jones Journal: J Am Soc Echocardiogr Date: 2020-11-17 Impact factor: 5.251